Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-059646
Filing Date
2026-05-20
Accepted
2026-05-20 17:21:51
Documents
63
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0291193-10q_abpro.htm   iXBRL 10-Q 631772
2 CERTIFICATION ea029119301ex31-1.htm EX-31.1 9314
3 CERTIFICATION ea029119301ex32-1.htm EX-32.1 3873
  Complete submission text file 0001213900-26-059646.txt   5425134

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abp-20260331.xsd EX-101.SCH 63672
5 XBRL CALCULATION FILE abp-20260331_cal.xml EX-101.CAL 27028
6 XBRL DEFINITION FILE abp-20260331_def.xml EX-101.DEF 329857
7 XBRL LABEL FILE abp-20260331_lab.xml EX-101.LAB 528155
8 XBRL PRESENTATION FILE abp-20260331_pre.xml EX-101.PRE 321440
67 EXTRACTED XBRL INSTANCE DOCUMENT ea0291193-10q_abpro_htm.xml XML 447753
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41224 | Film No.: 261005147
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)